本研究将为推动该疾病治疗学迈向靶向时代，进一步改写临床指南并最终改善患者预后提供有力的循证依据。仁济医院风湿科副主任医师吴万龙为该论文第一作者，风湿科主任叶霜教授为通讯作者。本研究得到广州医科大学附属第一医院呼吸科主任医师罗群、韩茜，浙江大学附属第二医院风湿科主任医师吴华香，温州医科大学附属第一医院风湿科主任医师孙莉，复旦大学附属华山医院风湿科主任医师万伟国、薛愉等合作团队的大力支持。此外，研究还 ...

在线发表了上海交通大学医学院附属仁济医院风湿科叶霜教授团队领衔的多中心真实世界研究《Effectiveness and safety of tofacitinib versus calcineurin inhibitor in ...

Received FDA orphan drug designation for the treatment of dermatomyositis in April 2017. Received FDA approval for the treatment of dermatomyositis in adults in July 2021. The mechanism of action ...

buying Rahko for its machine learning prowess and acquiring IFM Discovery for MDA5 and NLRP1 discovery programs. IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey CEO Gary ...

Department of Oncology, Yuhuangding Hospital, Affiliated with Medical College of Qingdao University, Yantai, Shandong, China Background: Dermatomyositis is an idiopathic inflammatory myopathy and ...

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Dermatomyositis is a ...